News ArchivesRead News

Your Parkinson's News Update for the Week of 6.8.20

Monday June 08, 2020
Insight into Protein Misfolding Could Open up
New Approaches to Treat Parkinson's
Nature Communications via Medical XPress
"The human brain contains a protein called alpha-synuclein (aSyn), which is found mainly at the tips of neurons in structures called pre-synaptic terminals. In Parkinson's and some other neurodegenerative disorders, the aSyn protein becomes destabilized, misfolds and aggregates into insoluble fibrils, a hallmark of Parkinson's."
"We wanted to understand why the normally healthy, monomeric and soluble aSyn suddenly starts to misfold," says Dr. Amberley Stephens, first co-author of the research paper, at the University of Cambridge Department of Chemical Engineering and Biotechnology.
Seattle Biotech Startup Athira Raises $85M to Develop Therapies for Alzheimer’s and Parkinson’s
"The foundation of Athira Pharma began while Leen Kawas was earning her Ph.D. in molecular pharmacology at Washington State University nearly a decade ago. Fast forward to today and the Seattle biotech startup is inching closer to FDA approval for its drug therapy that can restore brain function and help people suffering from brain diseases such as Alzheimer’s and Parkinson’s."
COVID-19 Impact on Parkinson's Disease Treatment Market
This report provides:
1) An overview of the global market for Parkinson's Disease Treatment Market and related technologies.
2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.
3) Identifications of new market opportunities and targeted promotional plans for Parkinson's Disease Treatment Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.